Compare Hims and Hers Health Inc (HIMS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs IDEXX Laboratories, Inc. — how do they compare? Hims and Hers Health Inc trades at $29.98 (market cap $7.12B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 6.5× Hims and Hers Health Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| HIMS | IDXX | |
|---|---|---|
Market Cap | $7.12B | $46.22B |
Sector | Health | Health |
52-Week High | $62.76 | $766.68 |
52-Week Low | $14.52 | $526.44 |
Enterprise Value | $7.82B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.
The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
